Abstract: The present invention provides a composition for delivering a protein vaccination candidate to a mammalian subject having a Leishmania transfected for expressing a cDNA sequence for encoding the protein vaccination candidate, and the Leishmania containing a photosensitizer.
Type:
Grant
Filed:
May 10, 2012
Date of Patent:
May 3, 2016
Assignee:
Rosalind Franklin University of Medicine and Science
Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.
Type:
Grant
Filed:
March 31, 2010
Date of Patent:
April 26, 2016
Assignee:
Colgate-Palmolive Company
Inventors:
Venda Porter, Andre Morgan, Michael Prencipe, Sarita Mello
Abstract: The composition for treating ocular effects of diabetes is a composition that contains an aldose reductase inhibitor in an ophthalmic gel for topical application to the eye. The composition includes a carrier having, by weight, about 0.4% carbomer, 4.0% sorbitol, 0.01% centrimide, 0.01% ethylenediaminetetraacetic acid (EDTA) and effective amounts of sodium chloride and sodium hydroxide for adjusting the pH of the topical carrier to about 7 and to achieve a desired viscosity, with the balance being water. The aldose reductase inhibitor (ARI) is mixed with the topical carrier at about 0.1%-6% by weight of the composition to form an ophthalmic gel. Preferably, the ARI is 2R,4S-6-fluoro-2-methyl-spiro[chroman-4,4?-imidazolidine]-2?,5?-dione, referred to as 2-methyl sorbinil, having the structure: or a pharmaceutically acceptable salt thereof. In use, the ophthalmic gel is preferably applied as an eye drop at a dosage of one drop per eye administered two to three times daily.
Abstract: The present invention provides a method for measuring oocyst of protozoa, such as Cryptosporidium, in an environment sample with high sensitivity at low cost within a short period of time; and a detecting reagent for use therein. Magnetic fine particles of 5 to 500 nm particle diameter having, immobilized thereto, binding factors for specific recognition of oocyst are added to an analyte containing a protozoan oocyst to form oocyst/binding factor/magnetic fine particle complexes by using a binding reaction to the oocyst, the formed complexes are recovered by a magnetic separation, and the protozoan oocysts contained in the complexes are assayed. Further, there is provided, for conducting the above method, a reagent for detecting protozoan oocysts comprising magnetic fine particles of 5 to 500 nm particle diameter having, immobilized thereto, antibodies against oocysts or binding factors for recognizing the antibodies.
Type:
Grant
Filed:
January 11, 2006
Date of Patent:
March 29, 2016
Assignees:
NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, JNC CORPORATION
Abstract: The invention provides compositions and fusion proteins comprising a flagellin adjuvant and a Pseudomonas aeruginosa antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against P. aeruginosa (e.g., to prevent and/or treat P. aeruginosa infection).
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
February 16, 2016
Assignee:
Wake Forest University Health Sciences
Inventors:
Steven B. Mizel, Daniel J. Wozniak, Eric T. Weimer
Abstract: Embodiments of the invention are directed to fibrillar adjuvants. Epitopes assembled into nanofibers by a short synthetic fibrillization domain elicited high antibody titers in the absence of any adjuvant.
Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.
Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.
Type:
Grant
Filed:
January 23, 2012
Date of Patent:
November 17, 2015
Assignee:
Human Genome Sciences, Inc.
Inventors:
Steven M. Ruben, Steven C. Barash, Gil H. Choi, Tristan Vaughan, David Hilbert
Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
Type:
Grant
Filed:
March 16, 2015
Date of Patent:
November 10, 2015
Assignees:
Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against Ehrlichia comprising a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to an antibody directed against a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a method of determining whether a subject is infected with Ehrlichia, comprising the steps of: contacting a sample from a subject with the antibody described herein; and detecting a resulting antibody reaction, wherein a positive reaction indicates the subject is infected with Ehrlichia.
Type:
Grant
Filed:
February 6, 2014
Date of Patent:
October 6, 2015
Assignee:
The Boards of Regents, of the University of Texas System
Abstract: The present invention provides a delayed and/or controlled release formulation of paroxetine or a pharmaceutically acceptable salt thereof that is formulated to release a substantial portion of the active ingredient (e.g., paroxetine) in the large intestine of an individual in need thereof. In one embodiment, the present invention provides a controlled release paroxetine composition comprising paroxetine or a pharmaceutically acceptable salt thereof, in a controlled release swallow pharmaceutical formulation, that upon administration, releases the paroxetine substantially in the large intestine. For example, the controlled release paroxetine formulation may be formulated to release greater than about 50% of the paroxetine in the large intestine.
Type:
Grant
Filed:
December 27, 2007
Date of Patent:
September 22, 2015
Assignee:
Mylan Specialty L.P.
Inventors:
Jason Neely, David J. Wargo, Boyong Li, Thomas D. Reynolds
Abstract: The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
September 22, 2015
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Inventors:
Steven A. Porcelli, Manjunatha M. Venkataswamy
Abstract: Described herein are methods for identifying a mammal having a heightened susceptibility to enamel erosion, together with kits therefor and uses and methods related thereto.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
September 22, 2015
Assignee:
Colgate-Palmolive Company
Inventors:
Lynette Zaidel, Steven Miller, Guy Carpenter, Gordon Proctor, David Bartlett, Rebecca Moazzez
Abstract: Vaccines comprising fliC and CD 154 polypeptides and Salmonella enteritidis vaccine vectors comprising fliC polypeptides are provided. Also provided arc methods of enhancing an immune response against flagellated bacteria and methods of reducing morbidity associated with infection with flagellated bacteria.
Type:
Grant
Filed:
October 30, 2008
Date of Patent:
September 8, 2015
Assignees:
The Board of Trustees of the University of Arkansas, The Texas A&M University System
Inventors:
Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Sherryll Layton
Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
Type:
Grant
Filed:
March 7, 2007
Date of Patent:
September 1, 2015
Assignees:
Institut Pasteur de Lille, Institut National de la Sante et da la Recherche Medicale
Abstract: The object of the invention is a polymeric depilatory (epilatory) composition including: a. at least one basic compound permitting adherence to the hair, b. at least one wax-based rheology regulating compound, and c. at least one microwave absorber compound.
Type:
Grant
Filed:
March 14, 2008
Date of Patent:
August 18, 2015
Assignee:
CHURCH & DWIGHT CO., INC.
Inventors:
Helena Cheminet, Ali Ben Moussa, Virginie Fera, Hubert Delagneau
Abstract: Methods and systems for detecting the presence of a target microorganism in a liquid sample are provided. Methods comprise the steps of passing the liquid sample through a surface filter, placing the surface filter into contact with a culture device, incubating the culture device for a period of time and detecting the presence of a target microorganism. Methods may be used with an automated detection system.
Type:
Grant
Filed:
December 18, 2008
Date of Patent:
August 4, 2015
Assignee:
3M Innovative Properties Company
Inventors:
Stephen B. Roscoe, Manjiri T. Kshirsagar, Cynthia D. Zook
Abstract: The invention provides compositions and fusion proteins comprising a flagellin adjuvant and a Pseudomonas aeruginosa antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against P. aeruginosa (e.g., to prevent and/or treat P. aeruginosa infection).
Type:
Grant
Filed:
March 16, 2010
Date of Patent:
August 4, 2015
Assignee:
Wake Forest University Health Sciences
Inventors:
Steven B. Mizel, Daniel J. Wozniak, Eric T. Weimer
Abstract: The present invention relates to a use of bacterial superantigens in the manufacture of a pharmaceutical composition for mucous membrane administration for the prevention of inflammatory disorders in newborn infants, such pharmaceutical compositions, as well as method for prevention of inflammatory disorders.
Type:
Grant
Filed:
June 4, 2009
Date of Patent:
July 21, 2015
Assignee:
SWECURE AB
Inventors:
Ingegerd Alderberth, Anna Rudin, Agnes E. Wold
Abstract: An object of the present invention is to provide an emulsifiable concentrate which comprises pyriproxyfen as an active ingredient, wherein the emulsifiable concentrate is excellent in emulsion stability under conditions of low-rate dilution not only in soft water but also in hard water. The present application provides for an emulsifiable concentrate excellent in emulsion stability which comprises pyriproxyfen, alkylarylsulfonic acid salt, polyoxyethylene styrylphenyl ether, polyoxyethylene castor oil, fatty acid C1-C6 alkyl ester, and aromatic hydrocarbon in specified amounts.